Biomarkers and targets for diagnosis prognosis and management of prostate disease
US6171796A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Aug 3, 1999 |
| Grant date | Jan 9, 2001 |
| Priority date | — |
| Expiry date | Aug 3, 2019 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S435/81
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Disclosed are diagnostic techniques for the detection of human prostate disease. The invention relates particularly to probes and methods for evaluating the presence of RNA species that are differentially expressed in metastatic prostate cancer compared to normal human prostate, benign prostatic hyperplasia, and non-metastatic prostate cancer. The invention also relates to probes and methods for evaluating the presence of RNA species that are differentially expressed in the peripheral blood of individuals with the disease state compared to normal healthy individuals. Described are methods of therapeutic use for genes identified as differentially expressed in metastatic prostate cancer, and means for screening pharmaceuticals effective in treatment of prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.